Can cholinesterase inhibitors provide additional effects to cholinergic neurotransmission enhancement?
The most frequent of the primary degenerative dementias is Alzheimer's disease (AD). The gradual loss of memory and attention in patients suffering from this illness are accompanied by aphasia, apraxia, agnosia, and alterations in visual-spatial perception. This group of symptoms is completed by emotional alterations, psychic instability, and changes in personality that appear in advanced phases of the illness. Different histopathological alterations have been described, like marked atrophy of the cerebral cortex with loss of cortical and subcortical neurons. Other histopathological hallmarks are the formation of senile plaques composed of beta-amyloid (Abeta) and neuro fibrillary tangles composed of hyperphosphorylation of tau protein.
López
Manuela G
MG
Instituto Teófilo Hernando, Universidad Autónoma de Madrid, Madrid, Spain. manuela.garcia@uam.es
Arias
Esperanza
E
Sobrado
Mónica
M
Lorrio
Silvia
S
Roda
José M
JM
García
Antonio G
AG
D000818:Animals; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D018678:Cholinergic Agents / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D005849:Gerbillinae; D005947:Glucose / Q000172:deficiency / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D006801:Humans; D002546:Ischemic Attack, Transient / Q000503:physiopathology; D009447:Neuroblastoma; D051381:Rats; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors; D005947:Glucose